Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...

Eli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Conversely, Eduardo Grunvald, MD, medical director of the weight management program at UC San Diego Health, sees less of an issue as long as there is a legitimate prescriber. Some of his patients have ...

GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or ...

Eli Lilly and Novo Nordisk dominate the market for weight loss drugs, and demand for their products has surpassed supply in recent times. Lilly’s weight loss portfolio has already delivered ...

Eli Lilly said on Wednesday ... Zepbound helped patients lose an average of 20% of their weight after 72 weeks compared to 14% for the group treated with Wegovy, Lilly said. Participants were ...

Share on Pinterest Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Shelby Knowles/Bloomberg via Getty Images Zepbound led to more long ...

Both weight-loss drug makers' stocks have slipped in recent months, but they remain in positive territory for the year. Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy ...

While Lilly’s trial that led to the approval of Zepbound showed an average body weight loss of 21% over 72 weeks, Novo’s study for Wegovy produced an average weight loss of 15% through 68 weeks.